全文获取类型
收费全文 | 129137篇 |
免费 | 44333篇 |
国内免费 | 605篇 |
专业分类
耳鼻咽喉 | 1847篇 |
儿科学 | 5542篇 |
妇产科学 | 691篇 |
基础医学 | 29391篇 |
口腔科学 | 6805篇 |
临床医学 | 15426篇 |
内科学 | 29709篇 |
皮肤病学 | 4701篇 |
神经病学 | 19299篇 |
特种医学 | 6174篇 |
外国民族医学 | 3篇 |
外科学 | 16091篇 |
综合类 | 2085篇 |
现状与发展 | 2篇 |
一般理论 | 8篇 |
预防医学 | 8665篇 |
眼科学 | 1531篇 |
药学 | 10792篇 |
中国医学 | 1863篇 |
肿瘤学 | 13450篇 |
出版年
2024年 | 16篇 |
2023年 | 245篇 |
2022年 | 431篇 |
2021年 | 2053篇 |
2020年 | 6376篇 |
2019年 | 11698篇 |
2018年 | 11323篇 |
2017年 | 12575篇 |
2016年 | 11659篇 |
2015年 | 11514篇 |
2014年 | 11542篇 |
2013年 | 12343篇 |
2012年 | 10781篇 |
2011年 | 10760篇 |
2010年 | 9379篇 |
2009年 | 5929篇 |
2008年 | 6570篇 |
2007年 | 4960篇 |
2006年 | 4706篇 |
2005年 | 4527篇 |
2004年 | 4415篇 |
2003年 | 4057篇 |
2002年 | 3818篇 |
2001年 | 2997篇 |
2000年 | 1852篇 |
1999年 | 694篇 |
1998年 | 433篇 |
1997年 | 481篇 |
1996年 | 521篇 |
1995年 | 479篇 |
1994年 | 549篇 |
1993年 | 422篇 |
1992年 | 472篇 |
1991年 | 490篇 |
1990年 | 377篇 |
1989年 | 316篇 |
1988年 | 332篇 |
1987年 | 263篇 |
1986年 | 242篇 |
1985年 | 431篇 |
1984年 | 326篇 |
1983年 | 195篇 |
1982年 | 191篇 |
1981年 | 74篇 |
1980年 | 79篇 |
1979年 | 36篇 |
1978年 | 33篇 |
1977年 | 36篇 |
1976年 | 21篇 |
1974年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2022,42(5):578-584
IntroductionThere is no consensus on the most appropriate treatment for chronic active antibody-mediated rejection (cAMR). Recent studies suggest that treatment with tocilizumab (TCZ) may stabilize graft function, decrease the intensity of donor-specific HLA antibodies (DSAs) and reduce inflammation of microcirculation.Patients and methodsObservational study with renal allograft recipients diagnosed with cAMR (n = 5) who had not submitted a response to traditional treatment based on the combination of plasma replacements, immunoglobulins, and rituximab. Patients were told to be treated with TCZ as compassionate use in six doses per month (8 mg/kg/month). Renal function, proteinuria, and the intensity of DSAs were monitored during follow-up.ResultsFive patients, average age 60 ± 13 years, three male and two retrasplants (cPRA average 55%) with preformed DSAs. Treatment with TCZ was initiated within 47 ± 52 days of biopsy. In two cases treatment was discontinued after the first dose, by severe bicitopenia with cytomegalovirus viremia and by graft failure, respectively. In the three patients who completed treatment, no stability of renal function (serum creatinine from 1.73 ± 0.70 to 2.04 ± 0.52 mg/dL, e-FGR 4 6 ± 15 to 36 ± 16 mL/min), showed increased proteinuria (3.2 ± 4.0 to 6.9 ± 11.0 g/g) and the intensity of DSAs maintain stable. No changes were observed in the degree of inflammation of microcirculation (g + pt 4.2 ± 0.8 vs. 4.3 ± 1.0) or in the degree of transplant glomerulopathy (cg 1.2 ± 0.4 vs. 1.8 ± 1.0).ConclusionsTCZ therapy does not appear to be effective in modifying the natural history of chronic active antibody-mediated rejection, does not improve the degree of inflammation of microcirculation and does not reduces the intensity of DSAs. 相似文献
2.
3.
4.
《Immunity》2022,55(9):1725-1731.e4
- Download : Download high-res image (182KB)
- Download : Download full-size image
5.
Phoebe Hammer Kevin White Stephanie Mengden Vessy Korcheva Philipp W. Raess 《Journal of cutaneous pathology》2019,46(5):343-346
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances. 相似文献
6.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
7.
8.
9.
Daniel Schar Pawin Padungtod Nguyen Tung Michael OLeary Wantanee Kalpravidh Filip Claes 《Influenza and other respiratory viruses》2019,13(6):618-621
Among the chief limitations in achieving early detection and control of animal‐origin influenza of pandemic potential in high‐risk livestock populations is the existing lag time between sample collection and diagnostic result. Advances in molecular diagnostics are permitting deployment of affordable, rapid, highly sensitive, and specific point‐of‐capture assays, providing opportunities for targeted surveillance driving containment strategies with potentially compelling returns on investment. Interrupting disease transmission at source holds promise of disrupting cycles of animal‐origin influenza incursion to endemicity and limiting impact on animal production, food security, and public health. Adoption of new point‐of‐capture diagnostics should be undertaken in the context of promoting robust veterinary services systems and parallel support for operationalizing pre‐authorized plans and communication strategies that will ensure that the full potential of these new platforms is realized. 相似文献
10.